DBV Technologies S.A. DBVT
DBV Technologies S.A. (Nasdaq: DBVT) is an immunology/inflammation drug developer. Its lead program, Viaskin Peanut patch, is in Phase 3 for Peanut allergy in children (4 through 7 years; also ages 1 through 3).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Viaskin Peanut patch (ages 4-7) | Peanut allergy | device-combination | Phase 3 |
| Viaskin Peanut patch (toddlers 1-3, COMFORT Toddlers safety study) | Peanut allergy | device-combination | Phase 3 |
| Viaskin Peanut patch (infants 6-12 months, THRIVE) | Peanut allergy | device-combination | Phase 2 |
Recent results and decisions
- Sep 30, 2026submitted DBV submitted its BLA to the FDA for VIASKIN Peanut Patch in children aged 4-7 and requested Priority Review (Breakthrough Therapy designation previously granted).
the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the VIASKIN® Peanut Patch in children with peanut allergy aged 4 through 7 years.
Filing - Sep 29, 2026submitted DBV Technologies submitted a BLA to the FDA for the VIASKIN Peanut Patch in children aged 4-7 years with peanut allergy, supported by the successful Phase 3 VITESSE trial.
The Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the VIASKIN® Peanut Patch in children with peanut allergy aged 4 through 7 years.
Filing - Jul 16, 2026started DBV initiated the Phase 2 THRIVE study of VIASKIN Peanut in infants 6-12 months, evaluating ad lib peanut consumption after 3-4 years of treatment.
Initiated the THRIVE study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in infants aged 6 through 12 months with peanut allergy
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.